Francesco Barale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesco Barale has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Pierluigi Politi
Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy
29 shared publications - Enzo Emanuele
E Science, I-27038 Robbio, PV, Italy
15 shared publications - Paolo Brambilla
University of Milan
12 shared publications - Paolo Fusar-Poli
Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
12 shared publications Edgardo Caverzasi
9 shared publications- Natascia Brondino
Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy
7 shared publications
Latest Publications
- 6 October 2015
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 46 (3) , 825-839
Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies
Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings.
- 6 October 2015
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- Vol. 46 (3) , 825-839
Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies
Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis. It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways. Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD. The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism. To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising. Of note, short-term use of all the reviewed medications appears to be safe. Future well designed trials are needed to elucidate these preliminary findings.
- Open Access
- 7 May 2015
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2015, 1-31
Complementary and Alternative Therapies for Autism Spectrum Disorder
Background. Complementary and alternative medicine (CAM) represents a popular therapeutic option for patients with autism spectrum disorder (ASD). Unfortunately, there is a paucity of data regarding the efficacy of CAM in ASD. The aim of the present systematic review is to investigate trials of CAM in ASD.Material and Methods. We searched the following databases: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CINAHL, Psychology and Behavioral Sciences Collection, Agricola, and Food Science Source.Results. Our literature search identified 2687 clinical publications. After the title/abstract screening, 139 publications were obtained for detailed evaluation. After detailed evaluation 67 studies were included, from hand search of references we retrieved 13 additional studies for a total of 80.Conclusion. There is no conclusive evidence supporting the efficacy of CAM therapies in ASD. Promising results are reported for music therapy, sensory integration therapy, acupuncture, and massage.
- 7 May 2015
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2015, 1-31
Open AccessComplementary and Alternative Therapies for Autism Spectrum Disorder
Background. Complementary and alternative medicine (CAM) represents a popular therapeutic option for patients with autism spectrum disorder (ASD). Unfortunately, there is a paucity of data regarding the efficacy of CAM in ASD. The aim of the present systematic review is to investigate trials of CAM in ASD.Material and Methods. We searched the following databases: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CINAHL, Psychology and Behavioral Sciences Collection, Agricola, and Food Science Source.Results. Our literature search identified 2687 clinical publications. After the title/abstract screening, 139 publications were obtained for detailed evaluation. After detailed evaluation 67 studies were included, from hand search of references we retrieved 13 additional studies for a total of 80.Conclusion. There is no conclusive evidence supporting the efficacy of CAM therapies in ASD. Promising results are reported for music therapy, sensory integration therapy, acupuncture, and massage.
- Open Access
- 22 January 2014
- Published by Wiley in The Scientific World Journal
- Vol. 2014, 1-6
Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies
Dementia is a leading health problem worldwide, with Alzheimer’s disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Severalin vitroandin vivostudies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy betweenin vitroandin vivofindings and human trials, such as low bioavailability and poor study design.
- 22 January 2014
- Published by Wiley in The Scientific World Journal
- Vol. 2014, 1-6
Open AccessCurcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies
Dementia is a leading health problem worldwide, with Alzheimer’s disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Severalin vitroandin vivostudies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy betweenin vitroandin vivofindings and human trials, such as low bioavailability and poor study design.
- 1 July 2013
- Published by Elsevier in Psychiatry Research
- Vol. 213 (1) , 18-23
Childhood abuse is associated with structural impairment in the ventrolateral prefrontal cortex and aggressiveness in patients with borderline personality disorder
- 1 July 2013
- Published by Elsevier in Psychiatry Research
- Vol. 213 (1) , 18-23
Childhood abuse is associated with structural impairment in the ventrolateral prefrontal cortex and aggressiveness in patients with borderline personality disorder
- 1 May 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 10 (3) , 245-253
Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: a review of the current literature.
Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
- 1 May 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 10 (3) , 245-253
Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: a review of the current literature.
Abstract: A growing body of evidence suggests that omega (ω)-3 polyunsaturated fatty acids (PUFAs) are clinically useful in patients with psychiatric disorders. In the present review, we summarize the findings of randomized, placebocontrolled clinical trials that have focused on the potential therapeutic utility of ω-3 PUFAs in patients with mental illnesses. We searched the PubMed database for placebo-controlled clinical trials using the keywords “PUFAs”, “omega-3”, “eicosapentaenoic acid”, and “docosahexaenoic acid” in combination with the following terms: “anxiety disorders”, “mood disorders”, “autism”, “attention-deficit hyperactivity disorder” (ADHD), “personality disorders”, and “schizophrenia”. The literature review indicated that personality disorders, autism, and anxiety disorders have been investigated less frequently than mood disorders, schizophrenia, and ADHD. Although no definite conclusions can be drawn on the therapeutic efficacy of ω-3 PUFAs in the majority of the psychiatric illnesses examined here, the evidence suggests that these molecules have a potential preventive role in people at extremely high risk for developing psychosis. Future studies in the field should examine ω-PUFAs turnover in neural membranes. Moreover, special attention should be paid to potential confounds, such as smoking and dietary habits.
- 1 April 2013
- Published by Taylor & Francis in Behavioral Medicine
- Vol. 39 (2) , 25-28
Association between Low-Activity Allele of Cathecolamine-O-Methyl-Transferase (COMT) and Borderline Personality Disorder in an Italian Population
The objective of the present study was to test the association between Borderline Personality Disorder (BPD) and the cathecolamine-O-methyl-transferase (COMT) low-activity (Met158) single nucleotide polymorphism (SNP). In this case-control study, DNA was obtained from venous blood of 19 BPD patients and 36 healthy subjects. COMT-Val158Met single-nucleotide polymorphism was genotyped by predesigned SNP assay. The COMT Met158 allele was over-represented in patients with BPD in comparison to normal subjects (68.4% vs 44.4%, respectively; Fisher exact test, p = .02). In terms of genotype, the Met158Met subjects were more frequent in patients versus controls (47.4% vs 22.2%, respectively), whereas the high-activity genotype Val158Val was under-represented (10.5% vs 33.3%, respectively). The allele encoding for the COMT with low enzymatic efficiency was found to be over-represented in BPD, possibly resulting in excessive synaptic dopaminergic activity and ultimately affecting externalizing behaviours, such as impulsivity and aggressiveness.
- 1 April 2013
- Published by Taylor & Francis in Behavioral Medicine
- Vol. 39 (2) , 25-28
Association between Low-Activity Allele of Cathecolamine-O-Methyl-Transferase (COMT) and Borderline Personality Disorder in an Italian Population
The objective of the present study was to test the association between Borderline Personality Disorder (BPD) and the cathecolamine-O-methyl-transferase (COMT) low-activity (Met158) single nucleotide polymorphism (SNP). In this case-control study, DNA was obtained from venous blood of 19 BPD patients and 36 healthy subjects. COMT-Val158Met single-nucleotide polymorphism was genotyped by predesigned SNP assay. The COMT Met158 allele was over-represented in patients with BPD in comparison to normal subjects (68.4% vs 44.4%, respectively; Fisher exact test, p = .02). In terms of genotype, the Met158Met subjects were more frequent in patients versus controls (47.4% vs 22.2%, respectively), whereas the high-activity genotype Val158Val was under-represented (10.5% vs 33.3%, respectively). The allele encoding for the COMT with low enzymatic efficiency was found to be over-represented in BPD, possibly resulting in excessive synaptic dopaminergic activity and ultimately affecting externalizing behaviours, such as impulsivity and aggressiveness.
- 1 December 2012
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 24 (6) , 349-355
Impaired working memory and normal sustained attention in borderline personality disorder
Lazzaretti M, Morandotti N, Sala M, Isola M, Frangou S, De Vidovich G, Marraffini E, Gambini F, Barale F, Zappoli F, Caverzasi E, Brambilla P. Impaired working memory and normal sustained attention in borderline personality disorder.Objective: Although reports in the literature describe deficits in working memory in borderline personality disorder (BPD), the evidence is limited and inconsistent. The aim of this study was to evaluate further this cognitive dimension and its clinical correlates in BPD.Method: We compared the performance of 15 BPD patients to 1:1 matched healthy controls on verbal working memory as determined by the sequential letter N-back test and sustained attention as measured using the continuous performance test (CPT).Results: BPD patients performed significantly worse on the N-back test compared to healthy controls (p < 0.05), but not on the CPT. The N-back deficit was more pronounced and significant in the 3-back condition and inversely correlated with impulsivity.Conclusions: These results suggest the presence of working memory deficits in BPD that may be linked to greater impulsivity and sustained by impairment in the dorsolateral prefrontal cortex.
- 1 December 2012
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 24 (6) , 349-355
Impaired working memory and normal sustained attention in borderline personality disorder
Lazzaretti M, Morandotti N, Sala M, Isola M, Frangou S, De Vidovich G, Marraffini E, Gambini F, Barale F, Zappoli F, Caverzasi E, Brambilla P. Impaired working memory and normal sustained attention in borderline personality disorder.Objective: Although reports in the literature describe deficits in working memory in borderline personality disorder (BPD), the evidence is limited and inconsistent. The aim of this study was to evaluate further this cognitive dimension and its clinical correlates in BPD.Method: We compared the performance of 15 BPD patients to 1:1 matched healthy controls on verbal working memory as determined by the sequential letter N-back test and sustained attention as measured using the continuous performance test (CPT).Results: BPD patients performed significantly worse on the N-back test compared to healthy controls (p < 0.05), but not on the CPT. The N-back deficit was more pronounced and significant in the 3-back condition and inversely correlated with impulsivity.Conclusions: These results suggest the presence of working memory deficits in BPD that may be linked to greater impulsivity and sustained by impairment in the dorsolateral prefrontal cortex.
- 13 June 2012
- Vol. 27 (1) , 13-22
Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature.
More and more neuroimaging studies are using in vivo proton magnetic resonance spectroscopy (1H-MRS) to explore correlates of response to therapy in major depressive disorder (MDD). Their aim is to further understanding of the effects of neurotransmitter changes in areas involved in MDD and the mechanisms underlying a good treatment response. We set out to summarise the literature from the past fifteen years on biochemical correlates of treatment response in MDD patients, reflected in pre- and post-therapy changes in 1H-MRS measurements. Our literature search identified fifteen articles reporting 1H-MRS studies in MDD treatment; no study used 1P-MRS. Despite the wide diversity of 1H-MRS methods applied, brain regions studied, and metabolite changes found, there emerged strong evidence of a correlation between changes in neurometabolite concentrations, in particular glutamate, N-acetylaspartate and choline, and a good treatment response to pharmacotherapy or antidepressant stimulation techniques.
- 13 June 2012
- Vol. 27 (1) , 13-22
Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature.
More and more neuroimaging studies are using in vivo proton magnetic resonance spectroscopy (1H-MRS) to explore correlates of response to therapy in major depressive disorder (MDD). Their aim is to further understanding of the effects of neurotransmitter changes in areas involved in MDD and the mechanisms underlying a good treatment response. We set out to summarise the literature from the past fifteen years on biochemical correlates of treatment response in MDD patients, reflected in pre- and post-therapy changes in 1H-MRS measurements. Our literature search identified fifteen articles reporting 1H-MRS studies in MDD treatment; no study used 1P-MRS. Despite the wide diversity of 1H-MRS methods applied, brain regions studied, and metabolite changes found, there emerged strong evidence of a correlation between changes in neurometabolite concentrations, in particular glutamate, N-acetylaspartate and choline, and a good treatment response to pharmacotherapy or antidepressant stimulation techniques.
- Top Cited PapersOpen Access
- 1 March 2012
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 69 (3) , 220-229
Predicting Psychosis
Although prodromal symptoms of psychosis have long been recognized,2 the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. For the past 15 years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms.3 This clinical syndrome has been termed an at risk mental state,4 and operationalized criteria—the ultra high risk (UHR)5 or clinical high risk (HR)6 criteria—have been developed to identify the syndrome.4 The criteria apply to young help-seeking patients and require 1 of 3 presentations:“attenuated” psychotic symptoms, full-blown psychotic symptoms that are brief and self-limiting, or a significant decrease in functioning in the context of a genetic risk for schizophrenia.7 Additional prodromal criteria emerging from the basic symptoms (BS) literature8 include subjective disturbances of cognitive processing and the perception of the self and the world.9 Belonging to one of these prodromal groups, which we hereafter term the clinical high risk syndrome, is associated with impairments in neuropsychologic performance10 and alterations in the structure11-13 (for meta-analyses, see Fusar-Poli et al14,15), function16-18 (for meta-analyses, see Smieskova et al19 and Fusar-Poli et al20), connectivity,21 and neurochemistry22-24 of the brain.
- 1 March 2012
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 69 (3) , 220-229
Top Cited PapersOpen AccessPredicting Psychosis
Although prodromal symptoms of psychosis have long been recognized,2 the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. For the past 15 years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms.3 This clinical syndrome has been termed an at risk mental state,4 and operationalized criteria—the ultra high risk (UHR)5 or clinical high risk (HR)6 criteria—have been developed to identify the syndrome.4 The criteria apply to young help-seeking patients and require 1 of 3 presentations:“attenuated” psychotic symptoms, full-blown psychotic symptoms that are brief and self-limiting, or a significant decrease in functioning in the context of a genetic risk for schizophrenia.7 Additional prodromal criteria emerging from the basic symptoms (BS) literature8 include subjective disturbances of cognitive processing and the perception of the self and the world.9 Belonging to one of these prodromal groups, which we hereafter term the clinical high risk syndrome, is associated with impairments in neuropsychologic performance10 and alterations in the structure11-13 (for meta-analyses, see Fusar-Poli et al14,15), function16-18 (for meta-analyses, see Smieskova et al19 and Fusar-Poli et al20), connectivity,21 and neurochemistry22-24 of the brain.